Department of Medicine, University of California San Francisco, San Francisco, CA, USA.
Division of Hematology and Oncology, University of California San Francisco, San Francisco, CA, USA.
Trends Cancer. 2020 Mar;6(3):174-177. doi: 10.1016/j.trecan.2020.01.003. Epub 2020 Feb 6.
Although immunotherapy has proved to be effective in a variety of cancer subtypes, the role of immune checkpoint inhibition in the treatment of prostate cancer remains unclear. Here we review results from the latest clinical trials and discuss data suggesting that certain genetic mutations may confer increased sensitivity to immune checkpoint blockade.
虽然免疫疗法已被证明在多种癌症亚型中有效，但免疫检查点抑制在前列腺癌治疗中的作用仍不清楚。在这里，我们回顾了最新临床试验的结果，并讨论了一些数据，这些数据表明某些基因突变可能使患者对免疫检查点阻断更敏感。
